Medicine and Dentistry
Human Immunodeficiency Virus
100%
Isoniazid
35%
Latent Tuberculosis
35%
Infectious Disease Treatment
25%
Health Care Cost
21%
Multidrug Resistant Tuberculosis
20%
Community-Based Intervention
19%
Lung Tuberculosis
19%
Foreign Born
16%
Tuberculosis Treatment
16%
Cluster Randomized Trial
16%
Antiretroviral Therapy
15%
Odds Ratio
13%
Alcohol Consumption
13%
Childhood Tuberculosis
13%
Men Who Have Sex with Men
13%
Extensively Drug Resistant Tuberculosis
13%
Physician Attitude
13%
Health Care
11%
Side Effect
11%
Skin Test
10%
Counseling
10%
Diseases
10%
Interferon Gamma Release Assay
9%
Cross Sectional Study
9%
HIV Test
8%
Prospective Cohort Study
8%
Sputum Smear
7%
Drug Resistant Tuberculosis
7%
Tuberculin
7%
Logistic Regression Analysis
7%
Infection
7%
Mantoux Test
6%
Primary Health Care
6%
MHealth
6%
Awareness
6%
Moxifloxacin
6%
Tuberculosis Diagnosis
6%
Treatment Interruption
6%
Randomized Clinical Trial
6%
Release Assay
6%
Randomized Controlled Trial
6%
Gamma Interferon
6%
Interleukin 10
6%
Interferon
6%
Pediatrics
6%
Vaccine Hesitancy
6%
Depressive Disorder
6%
Pre-Exposure Prophylaxis
6%
Treatment Duration
6%
Nursing and Health Professions
Human Immunodeficiency Virus
79%
Health Care Personnel
43%
Isoniazid
39%
Latent Tuberculosis
35%
Health Care Facility
31%
Antiretroviral Therapy
22%
Health Care Quality
19%
Odds Ratio
16%
Confidence Interval
15%
Multi-Drug-Resistant Tuberculosis
13%
Pill
13%
Systematic Review
13%
Pilot Study
13%
Extensively Drug-Resistant Tuberculosis
13%
Foreign Born
12%
Practice Guideline
11%
Interferon Gamma Release Assay
10%
Treatment Duration
10%
Patient Compliance
9%
Skin Test
8%
World Health Organization
8%
Side Effect
8%
Prevalence
8%
Healthcare System
7%
Tuberculin Test
7%
Tuberculin
7%
Lung Tuberculosis
7%
Racial Group
6%
Cross-Sectional Study
6%
Adolescent
6%
Alcohol Consumption
6%
Physician Attitude
6%
Release Assay
6%
Interactive Voice Response System
6%
Symptomatology
6%
Prospective Cohort Study
6%
Primary Medical Care
6%
Interferon
6%
Treatment Interruption
6%
Mycobacterium Tuberculosis Test Kit
5%
Diseases
5%
Directly Observed Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
72%
Latent Tuberculosis
51%
Isoniazid
48%
Tuberculin
22%
Lung Tuberculosis
16%
Gamma Interferon
13%
Tablet
13%
Prospective Cohort Study
13%
Tolerability
9%
Multi-Drug-Resistant Tuberculosis
6%
Randomized Controlled Trial
6%
Tumor Necrosis Factor
6%
Randomized Clinical Trial
6%
Human Immunodeficiency Virus Infection
6%
Moxifloxacin
6%
Interferon
6%
Opiate
6%
Interleukin 10
6%
Pandemic
6%
COVID-19 Vaccine
6%
Depressive Disorder
6%
Cross Sectional Study
6%
Clinical Trial
5%
Su mensaje fue enviado correctamente.
Su mensaje no fue enviado debido a un error.